Slide

Your Partner in Life Sciences Transformation

The Dedham Group is a top-tier strategy consulting firm to propel you toward unparalleled commercial success.

With robust data, highly specialized expertise, and 360-degree perspective on the stakeholder experience, we are your go-to partner to transform commercial models, revamp market positioning, and ensure better patient access to care.

Learn More

Unparalleled Results

Our expert think-tank cuts through the “noise” to unearth actionable insights and cross-functional strategic recommendations to shatter payer, provider and patient access barriers.

Expert Insights

With over two decades of experience in the most complex healthcare categories, our dedicated teams of subject matter experts in oncology, immunology, rare disease, and other specialty spaces are in a league of their own.

Consider us your preferred partners for strategic direction across payer, provider, distribution and support channels, with a focus in access, pathways, pricing, contracting and customer engagement.

Let’s elevate your market access journey together.

Breaking Down Barriers,
One Client, One Story at a Time

IRA Strategy: Navigating Changes for Patient Support Programs in 2025

By Rebecca Leemputte The Inflation Reduction Act (IRA) has triggered significant shifts in the healthcare landscape, with profound implications for patient access and affordability. Earlier this month, I discussed how life sciences organizations can address these challenges as a panelist on AssistRx’s webinar, Ahead of the Curve: Considerations for Your 2025 Patient Support Program. As […]

Defining “Academic” Cancer Centers: Navigating the Ambiguity

“How many academic cancer centers are there in the United States?” is a question that will receive answers ranging from 30 to well over 100, depending on who you ask. The confusion surrounding the definition of an academic cancer center can be attributed to many factors, but the reality is that the lack of clarity can have real-world implications on both patients and manufacturers.

The State of Patient Access

How pharma leaders today are planning for potential access problems tomorrow.

The FDA’s PDURS Guidance: What Manufacturers Need to Know

In September 2023, the FDA released a new guidance document titled Regulatory Considerations for Prescription Drug Use-Related Software (PDURS). This guidance outlines how the FDA intends to apply its drug labeling authorities to software outputs associated with prescription drugs or drug-device combination products. It also opens several opportunities for brand differentiation and commercial success. Here’s what pharma manufacturers need to know about this guidance and how to prepare.

Overcoming Barriers: How Manufacturers Can Tackle Reimbursement Challenges for Cell & Gene Therapies

Cell and gene therapies (CGT) are revolutionary medical treatments that offer potential cures for previously untreatable diseases. However, the high cost and complex logistics associated with these therapies pose significant challenges for reimbursement, hindering patient access. To navigate these obstacles, manufacturers need to take strategic approaches involving various stakeholders in the healthcare ecosystem.

Understanding Access Barriers in 2024 and Beyond

Navigating the landscape of patient access in the pharma industry has become increasingly complex, extending far beyond traditional channels. The challenges are multifaceted, influenced by evolving policies, innovative payer strategies, and shifts in provider dynamics.

The Portfolio Optimization Balancing Act: Keys to Improving Business Outcomes

A well-balanced and diversified pharma product portfolio has countless advantages: it brings in new revenue streams, mitigates risk, facilitates market expansion, and supports business development efforts. Moreover, investors are often seeking diversified portfolios, which can improve access to capital.

Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers

Despite the rapid evolution of personalized medicine, access to genetic testing and next-generation sequencing (NGS) is a challenge—due in no small part to coverage confusion. Physicians struggle to navigate poorly defined testing coverage policies and a fragmented payer and vendor ecosystem, resulting in delayed care for patients requiring precision therapies.

The Clinical Trials Connection: How Cell & Gene Therapy Clinical Trial Design Impacts Commercial Access

By Katie Moses, Principal, Director of Cell and Gene Therapy Strategy and Jen Klarer, Partner, Head of Cell and Gene Therapy In high-cost categories like cell and gene therapy, clinical trial design has increasingly had implications on commercial access. Since trials are critical to obtaining FDA approval, pharma companies have focused heavily on demonstrating efficacy […]

How Virtual Care and Digital Pharmacies are Transforming the Healthcare Experience

If you’ve tuned into the news within the past few months, you’ll have seen Mark Cuban discussing his plans to lower pharmacy drug costs for patients. His namesake pharmacy, Mark Cuban Cost Plus Drug Company (MCCPDC), aims to manufacture and deliver low-cost therapies at a flat, transparent 15% markup plus a pharmacist fee. From digital pharmacies to other methods of virtual care, the healthcare experience is undergoing a rapid transformation. While care delivery models are still evolving, they bring new opportunities for pharma to increase value to patients.

Customer-Centric & Client-First

We prioritize your success, elevating your internal and external positioning to fuel commercial excellence.

Our relationship-driven business delivers a white-glove experience, with high-touch expert support in simplifying our complex access environment.

“With so much change and noise, it’s hard to focus our people and resources, and no one is closer to the customer than Dedham, which gives us a huge competitive edge on a daily basis.”

VP, Oncology Franchise

"The Dedham Group is very data-driven and their output is always actionable because they know how to help us implement…we rely heavily on them as a priority partner."

Executive Director, Market Access